저 골밀도에 대한 Bisphosphonate와 폐경후 호르몬 복합치료에 대한 연구
The Study of Bisphosphonate and Postmenopausal Hormone Treatment in Low Bone Mineral Density
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To evaluate the effect of postmenopausal hormone therapy alone or in combination with bisphosphonate on bone mineral density (BMD) in postmenopausal women. Methods: One hundred three women diagnosed with low BMD in postmenopausal women were included in this study. All patients were classified into two groups; oarl hormone therpy alone (Group I) or with alendronate (Group II), given for 12 months. Dual energy X-ray absorptiometry was used to measure BMD before and after 12 months of treatment. Results: In all groups, significant increase in bone density measurements were seen at 12 months of treatment. The BMD of lumbar spine more increased significantly in Group II than Group I. Conclusions: Postmenopausal hormone therapy is effective in osteopenic and osteoporotic women. However, the combined treatment with hormone therapy and bisphophonate is more effective in postmenopausal women with low BMD.
Abstract
Objectives: To evaluate the effect of postmenopausal hormone therapy alone or in combination with bisphosphonate on bone mineral density (BMD) in postmenopausal women. Methods: One hundred three women diagnosed with low BMD in postmenopausal women were included in this study. All patients were classified into two groups; oarl hormone therpy alone (Group I) or with alendronate (Group II), given for 12 months. Dual energy X-ray absorptiometry was used to measure BMD before and after 12 months of treatment. Results: In all groups, significant increase in bone density measurements were seen at 12 months of treatment. The BMD of lumbar spine more increased significantly in Group II than Group I. Conclusions: Postmenopausal hormone therapy is effective in osteopenic and osteoporotic women. However, the combined treatment with hormone therapy and bisphophonate is more effective in postmenopausal women with low BMD.
참고문헌 (21)
- Michaelsson K, "Hormone replacement therapy and risk of hip fracture: population based case-control study", BMJ, 316, pp.1858~1863 (1998)
- Heaney RP, "Bisphosphonate effects and the bone remodelling", J Bone Miner Res, 12, pp.1143~1151 (1997)
- Onvural A, "Hormone replacement therapy in postmenopausal osteoporosis, in Menopause and osteoporosis", pp.407~420 (2000), Istanbul
- Bone HG, "Alendronate and estrogen effects in postmenopausal women with low bone mineral density", J Clin Endoclinol Metab, 85, pp.720~726 (2000)
- Smith DM, "Age and activity effects on rat bone mineral loss", J Clin Invest, 58, pp.716~720 (1976)
- Christiansen C, "Prediction of rapid bone loss in postmenopausal women", Lancet, 1, pp.1105~1108 (1987)
- Yano K, "The relationship between diet and bone mineral content of multiple skeletal sites in elderly Japanese - American men and women living in Hawaii", Am J Clin Nutr, 42, pp.877~888 (1985)
- Daniell HW, "Osteoporosis of the slender smoker", Arch Intern Med, 136, pp.298~304 (1976)
- Feitelberg S, "Deranged bone mineral metabolism in chronic alcoholism", Metabolism, 36, pp.322~326 (1987)
- Heaney RP, "Calcium nutrition and bone health in the elderly", Am J Clin Nutr, 36, pp.986~1013 (1982)
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, "WHO study group", WHO, 843~ (1994)
- Lufkin EG, "Three-year follow-up on effects of transdermal estrogen", Ann Intern Med, 125, pp.77~ (1996)
- Prince RL, "A cohort study of the effect of endogenous estrogen on spine fracture risk and bone structure in elderly women and an assessment of its diagnostic usefulness", Bone, 41, pp.33~38 (2007)
- Tonino RP, "Long term (7-year) efficacy and tolerability of alendronate, and effect of discontinuation. The Phase 3 Osteoporosis Treatment Study Group", J Clin Endocrinol Metab, 85, pp.3109~3115 (2000)
- Davas I, "Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women", Fertil Steril, 80, pp.536~540 (2003)
- Fleisch H, "Bisphosphates: pharmacology and use in the treatment of tumor-induced hypercalcemia of metastatic bone disease", Drug, 42, pp.919~944 (1991)
- Bone HG, "Alendronate and estrogen effects in postmenopausal women with low bone mineral density", J Clin Endoclinol Metab, 85, pp.720~726 (2000)
- Writing Group for the Women's Health Initiative Investigators, "Risk and benefit of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative (WHI) randomized controlled trial", JAMA, 288, pp.321~323 (2002)
- Wells G, "Meta-analyses of therapies for postmenopausal osteoporosis. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women", Endocr Rev, 23, pp.529~539 (2002)
- Lindsay R, "Effect of lower dose of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women", JAMA, 287, pp.2668~2676 (2002)
- Lindsay R, "Addition of alendronate to ongoing HTR in the treatment of osteoporosis: a randomized, controlled clinical trial", J Clin Endocrinol Metab, 84, pp.3076~3081 (1999)